During the course of an ongoing project to prepare farnesyltransferase (FTase) inhibitors as potential drug candidates in an anti-cancer program targeting tumors with ras mutations, 1) we found CAAX peptidomimetics, such as 1-6, to have very good in vitro potency against FTase (Fig. 1) .
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Trans-isomers, such as 1, were less active against the enzyme than cis-isomers (e.g., 3). Furthermore, one such compound (6) showed interesting specificity for inhibition of geranylgeranyltransferase I (GGTase I) vs. FTase in a whole cell assay.
In order to expand the structure-activity relationship of this class of inhibitor, we examined the effects of changes at the 4-position of the hydroxyproline in compounds of type 3 (and the corresponding esters, 4) by preparing a number of analogs in which the ether oxygen was replaced by a sulfur atom or an alkyl chain or removed completely, while keeping the remainder of the peptidomimetic scaffold intact. In particular, we wished to examine how replacement of oxygen with carbon or sulfur might affect the lipophilicity or stability of such compounds.
Chemistry Thioether compounds 3) were prepared by S N 2 displacement of mesylate 7 with 4-isopropylthiophenol to give 8. The yield of this reaction was low (15%), but 7 could be recovered (81%) and recycled. Attempts to prepare 8 using standard Mitsunobu conditions (as used in the preparation of compounds 1-6) failed to give any of the desired product. Arylalkyl derivatives with a one-carbon linker connecting the aromatic group to the proline were prepared as shown in Chart 2. N-Boc-trans-4-hydroxy-L-proline methyl ester (9) was oxidized to ketone 10 under Swern conditions. The ketone was converted under Wittig conditions 3a) to a mixture of olefins (11). Hydrogenation of 11 gave 12 as a 2.5 : 1 mixture of diastereomers. These isomers were not readily separable neither at this stage nor at subsequent stages in the synthetic sequence. The major isomer was assumed to be the cis-isomer (hydrogenation from the less hindered face) based on a literature precedent 4) and 1 H-NMR analysis. This mixture was carried forward, and, as the final compounds did not display any improved qualities over analogs 3-6 (see Discussion), the individual isomers were never separated. Arylalkyl derivatives with a two-carbon linker were prepared as shown in Chart 3. N-Boc-trans-4-hy-droxy-L-proline methyl ester (9) was converted to the cisiodide 5) (13) under Mitsunobu-type conditions. The iodide was treated with AIBN/n-Bu 3 SnH in the presence of p-isopropylstyrene to give 14 as a mixture of cis-and trans-isomers (as determined by 1 H-NMR). 6) Once again, this pair of compounds was evaluated as a mixture since the isomers were not readily separable by silica gel chromatography or reverse phase HPLC.
Aryl-substituted derivatives with no linker were prepared as shown in Chart 4. Ketone 10 was converted into enol triflate 15 in moderate yield. 7) This triflate was cross-coupled with various arylboronic acids under palladium catalysis (Suzuki coupling 8) ) to give 16 in good yield. 7, 8) We found it more convenient to use Stille's catalyst 9) in place of the more air-sensitive Pd(PPh 3 ) 4 in these cross-coupling reactions. Hydrogenation of each alkene gave a single isomer ( 1 H-NMR), assumed to be the cis-isomer by a literature precedent for related hydrogenations.
3a)
For each target series, the remainder of the synthesis 2) was completed by carrying out the necessary steps as shown in Charts 5 and 6.
Discussion
Screening results for the compounds described above are summarized in Table 1 . The values for compounds 1-6 are presented for comparison. The in vitro assays 10) used recombinant FTase or GGTase, and measured the intrinsic activity and selectivity of the carboxylic acid forms of the analogs for inhibition of protein prenylation. The whole-cell assays used activated H-ras transfected NIH3T3 fibroblasts 10) and measured protein processing (H-ras or Rap 1A) in the presence of the methyl ester form of the inhibitors.
As can be seen in Table 1 , every modification described herein led to compounds less active than compounds 3-6. Thus, replacement of the ether oxygen with sulfur or carbon neither improved in vitro activity, nor improved activity in whole cells. In general, the carboxylic acids (25) were more active against FTase than GGTase I in vitro, with the exception of compound 25c which was somewhat more potent against GGTase I than FTase in vitro (Table 1) , and the corresponding methyl ester (26c) showed the same trend in whole cells. Interestingly, compounds 26a and 26e were slightly more potent in their inhibition of Rap 1A processing (GGTase I) than in their inhibition of H-ras processing in whole cells, although their corresponding carboxylic acids (25a, 25e) were slightly more potent in their inhibition of FTase in vitro. We currently have no explanation for this curious phenomenon.
In summary, we have prepared a series of CA 1 A 2 X peptidomimetic isoprenyltransferase inhibitors based on hydroxyproline at the A 2 position, and although none of the compounds prepared in this study offered significant improvement over the most potent that we reported previously (3-6), 2) nonetheless several were relatively potent inhibitors of FTase or GGTase I in vitro. We found no evidence that replacing or removing the ether oxygen in compounds such as 3-6 improved the stability or lipophilicity. However, this class of compounds expands the field of isoprenyltransferase inhibitors and may be useful in future development of anticancer drugs. 
